Simpson Thacher represented Pharmaceutical Product Development, LLC (“PPD”) in connection with Accelerated Enrollment Solutions’ (“AES”) acquisition of the clinical research site business of Bioclinica, a Cinven portfolio company. Accelerated Enrollment Solutions is a business unit of PPD that offers sponsors and contract research organizations best-in-class site conduct and patient access solutions. The acquisition extends AES’ reach into new geographies in China, Latin America and Western Europe, augmenting its strong presence in North America, Europe and South Africa. The transaction includes research sites from the merger of Bioclinica and CCBR-SYNARC in 2014. AES also expands its therapeutic area scope within the United States, adding four dedicated research sites in Florida, branded Compass Research, with significant expertise in neuroscience.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.
The Simpson Thacher team included Naveed Anwar, Benjamin Bodurian, Vinay Mysoor, Bob Zhao, David Wuchenich, Elaine Zhou and Anna LeGrett (M&A); Jeannine McSweeney, Alisa Tschorke and Ashlie Lawton (Executive Compensation and Employee Benefits); Sarah Katz and Abigail Hopper (Tax); Marcela Robledo and Ben Carson (Intellectual Property); Timothy Mulvihill (Environmental); Krista McManus (Real Estate); Steven DeLott (R&W Insurance); and Dean Masuda (Credit).